Checkpoint inhibitor real world outcomes in melanoma similar to RCTs

Real world patient outcomes with immune checkpoint inhibitors in metastatic melanoma match the survival outcomes and toxicities seen in randomised controlled trials, UK experience shows. The findings come from a review of NHS cancer databases for more than 2300  patients with melanoma treated with pembrolizumab, ipilimumab, nivolumab, and combinations of ipilimumab and nivolumab between 2014 ...

Already a member?

Login to keep reading.

© 2022 the limbic